Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
50 hedge funds and large institutions have $2.81M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
4% less funds holding
Funds holding: 52 → 50 (-2)
14% less capital invested
Capital invested by funds: $3.26M → $2.81M (-$458K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
+$98.2K |
| 2 |
RB
Richmond Brothers
Jackson,
Michigan
|
+$71.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.3K |
| 4 |
Renaissance Technologies
New York
|
+$9.26K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$7.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$203K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$12.4K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
-$11.5K |
| 4 |
Two Sigma Advisers
New York
|
-$10.4K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$8.17K |
ONCT Hedge Fund Activity: Q3 2023 in Review
50 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2023, worth a combined $2.81M — down 14% from $3.26M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ONCT and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 13 added.
The largest buyer was Pasadena Private Wealth, opening a new position worth an estimated $98.2K. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $203K sold.
- 50 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2023, down from 52 in Q2 2023.
- Funds reported $2.81M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2023, down 14% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of -2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2023 was Pasadena Private Wealth, an estimated $98.2K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2023 was Kennedy Capital Management, an estimated $203K sold.
Based on aggregated 13F filings for Q3 2023.